Ultragenyx Pharmaceutical (RARE) Consolidated Net Income (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Consolidated Net Income data on file, last reported at -$185.0 million in Q1 2026.

• On a quarterly basis, Consolidated Net Income fell 22.52% year-over-year to -$185.0 million in Q1 2026; TTM through Mar 2026 was -$602.9 million, a 10.56% decrease from a year earlier, with the FY2025 full-year figure at -$569.0 million, down 0.71% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$185.0 million, down from -$122.6 million in the prior quarter.
• Over the last five years, Consolidated Net Income for RARE reached as high as -$115.0 million in Q2 2025 and fell as low as -$245.1 million in Q3 2022.
• Historically, Consolidated Net Income has averaged -$155.0 million across 5 years, with a median of -$153.5 million in 2022.
• Across the five-year window, Consolidated Net Income plunged 235.77% in 2022 and surged 34.87% in 2023, its largest moves.
• Year by year, Consolidated Net Income stood at -$153.5 million in 2022, then grew by 19.5% to -$123.6 million in 2023, then dropped by 4.57% to -$129.2 million in 2024, then advanced by 5.14% to -$122.6 million in 2025, then slumped by 50.95% to -$185.0 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were -$185.0 million in Q1 2026, -$122.6 million in Q4 2025, and -$180.4 million in Q3 2025.